Advertisement
Canada markets close in 3 hours 40 minutes
  • S&P/TSX

    21,917.18
    +93.96 (+0.43%)
     
  • S&P 500

    5,120.56
    +56.36 (+1.11%)
     
  • DOW

    38,645.09
    +419.43 (+1.10%)
     
  • CAD/USD

    0.7310
    -0.0004 (-0.06%)
     
  • CRUDE OIL

    78.49
    -0.46 (-0.58%)
     
  • Bitcoin CAD

    84,422.47
    +3,698.43 (+4.58%)
     
  • CMC Crypto 200

    1,331.10
    +54.12 (+4.24%)
     
  • GOLD FUTURES

    2,302.70
    -6.90 (-0.30%)
     
  • RUSSELL 2000

    2,035.31
    +19.20 (+0.95%)
     
  • 10-Yr Bond

    4.5040
    -0.0670 (-1.47%)
     
  • NASDAQ

    16,137.40
    +296.45 (+1.87%)
     
  • VOLATILITY

    13.79
    -0.89 (-6.06%)
     
  • FTSE

    8,213.49
    +41.34 (+0.51%)
     
  • NIKKEI 225

    38,236.07
    -37.98 (-0.10%)
     
  • CAD/EUR

    0.6788
    -0.0029 (-0.43%)
     

Glaukos to Release First Quarter 2024 Financial Results after Market Close on May 1

Conference Call and Webcast Scheduled for 1:30 p.m. PT

ALISO VIEJO, Calif., April 10, 2024--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release first quarter 2024 financial results after the market close on Wednesday, May 1, 2024. The company’s management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) on May 1, 2024.

A link to the live webcast will be available on the company’s website at http://investors.glaukos.com. To participate in the conference call, please dial 888-210-2212 (U.S.) or 646-960-0390 (International) and enter Conference ID 7935742. A replay will be archived on the company’s website following completion of the call.

ADVERTISEMENT

About Glaukos

Glaukos (www.glaukos.com) is an ophthalmic pharmaceutical and medical technology company focused on developing and commercializing novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Glaukos first developed Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional glaucoma treatment paradigm, launching its first MIGS device commercially in 2012, and continues to develop a portfolio of technologically distinct and leverageable platforms to support ongoing pharmaceutical and medical device innovations. Products or product candidates for each of these platforms are designed to advance the standard of care through better treatment options across the areas of glaucoma, corneal disorders and retinal diseases.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240410647328/en/

Contacts

Chris Lewis
Vice President, Investor Relations and Corporate Affairs
(949) 481-0510
clewis@glaukos.com